Authors
Latest:
Dr. Strauss on Future Research Directions in SCLCJoshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.
Latest:
Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCTSanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.
Latest:
Fostering Interactions That HealThe pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.
Latest:
Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic CancersBradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.
Latest:
Empowering Community Cancer Care: Importance of Outreach InitiativesIn this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer.
Latest:
Dr Garcia-Manero on the Association Between Hemoglobin Levels and QOL in Lower-Risk MDSGuillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.
Latest:
Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific SurvivalAlexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.
Latest:
Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR AlterationsJames Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.
Latest:
Dr. Khan on the Ideal Patients for GnRH Agonists in Breast CancerZaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.
Latest:
Dr. Kröger on Toxicities Associated With Allogeneic Stem Cell Transplant in MyelomaNicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.
Latest:
Investigational Agents, Clinical Trials for Advanced HER2+ Breast CancerJoyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.
Latest:
Dr Garmezy on Findings From the Duravelo-1 Trial in Metastatic Urothelial CarcinomaBenjamin Garmezy, MD, discusses the phase 1/2 Duravelo-1 trial investigating zelenectide pevedotin in patients with metastatic urothelial carcinoma.
Latest:
Dr. Ferrarotto on the Mechanism of Action of Trilaciclib in ES-SCLCRenata Ferrarotto, MD, discusses the mechanism of action of trilaciclib in extensive-stage small cell lung cancer.
Latest:
Dr Ma on Sintilimab Plus Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaJun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Latest:
Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile CancerFernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.
Latest:
Dr Townsend on the Future Analysis of Prostate Cancer Driver Mutations Using Neoplasm Tissue SamplesJeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.
Latest:
Dr. Shi on the Rationale to Evaluate a Tumor-Treating Fields Therapy–Based Combination in GlioblastomaWenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.
Latest:
Dr Gallagher on Unmet Needs With ADCs in Breast CancerChristopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.
Latest:
Dr Tao on the Efficacy of Avelumab/Cetuximab/Radiotherapy in Cisplain-Eligibile vs Ineligible HNSCCYungan Tao, MD, discusses the efficacy of avelumab plus cetuximab and radiotherapy in patients with head and neck squamous cell carcinoma.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Dr Mohty on the Potential Role of BCMA-Targeted Bispecific Antibodies in MyelomaMohamad Mohty, MD, PhD, discusses the potential role of BCMA-targeted bispecific antibodies in myeloma.
Latest:
Overcoming Racial Inequality in Epithelial Ovarian Cancer ResearchDanja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.
Latest:
Dr Naik on the Evolving Role of Bispecific Antibodies in Multiple MyelomaSeema G. Naik, MD, discusses the evolving role of bispecific antibodies in hematologic malignancies.
Latest:
Dr Ramsey on Signs and Symptoms of Pneumonitis in Locally Advanced NSCLCMeghan Ramsey, MD, discusses signs and symptoms of pneumonitis in locally advanced non–small cell lung cancer.
Latest:
Dr. Hewitt on Considerations for Conservation Vs Mastectomy in Breast CancerKelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.
Latest:
Epidemiology, Treatment of an Aging Inflammatory Bowel Disease PopulationAdam S. Faye, MD, of NYU Grossman School of Medicine, discusses the epidemiology and treatment for aging patients with inflammatory bowel disease.
Latest:
Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEsPankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
Latest:
Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
Latest:
Dr. Dhir on Ongoing Research Efforts in Epithelioid and Synovial SarcomaAditi Dhir, MD, discusses ongoing efforts in epithelioid and synovial sarcoma.
